United Therapeutics.
biotech company based in Silver Spring, Maryland, United States
- Reports this week
- 3
- Active events
- 4
- Connections
- 75
What's happening
Active this week
-
Various financial institutions, including Royal Bank of Canada, Bank of America, Raymond James Financial, TD Cowen, Cantor Fitzgerald, and MarketBeat, issued rating and price target updates regarding United Therapeutics on July 10, 2026.Some support6 reports
-
Paul A. Mahon was named EVP and General Counsel at United Therapeutics.Some support1 report
-
Liquidia faced antitrust cases in New Jersey and trade secret cases in North Carolina, resulting in a settlement.Some support1 report
-
Court found Yutrepia, a product from Liquidia, infringed on United Therapeutics' patent.Some support2 reports
Earlier this month
One to three months ago
-
United Therapeutics acquired the former Anheuser-Busch brewery site in Merrimack.Some support1 report
-
United Therapeutics and Zenas are two healthcare companies that are currently competing for market share.Some support1 report
-
HCRx provided $50M funding to Liquidia, accelerating YUTREPIA's commercial launch while United Therapeutics filed an injunction request.Well supported5 reports
-
United Therapeutics and Baylor College of Medicine formed a research agreement to fund a Xeno research center investigating xenotransplantation.Some support1 report
-
United Therapeutics completed facility construction in Minnesota and Texas and submitted an NDA to the FDA.Some support1 report
-
Norges Bank purchased a new stake in shares of United Therapeutics on July 24, 2026.Some support1 report
Gone quiet
No new reports in 90+ days-
United Therapeutics filed required documents for executive stock transactions and listed its stock on the exchange.Some support1 report1 development inside
-
United Therapeutics disclosed stock sales by CEO Martine Rothblatt via required SEC filing.Well supported5 reports
-
The FDA granted premarket approval for the LungFX device for use with United Therapeutics, while Leerink partners maintained an Outperform rating on the company's shares.Some support2 reports
-
Filing required for institutional investment disclosures by Synaptics with the SEC.Some support2 reports
-
United Therapeutics filed disclosures with the Securities and Exchange Commission on June 16, 2026.Some support1 report
-
Analyst report boosted United Therapeutics' price target from $525 to $625.Some support1 report
-
UTHR stock benefits from Trump-era tariffs and onshoring.Some support2 reports
-
United Therapeutics is a biotech company based in Silver Spring, Maryland.Speculative1 report
-
Martine Rothblatt, CEO, provided company strategy updates for United Therapeutics on June 25, 2025.Some support3 reports
-
United Therapeutics provided updates on operational efficiency and trial standardization efforts in August 2025.Some support2 reports1 development inside
-
UBS adjusted its price target on United Therapeutics on June 30, 2025.Speculative1 report
-
Moderna and United Therapeutics are companies operating in the therapeutics industry.Some support1 report
-
United Therapeutics and Gilead Sciences are identified as major players in the therapeutics industry.Some support1 report
-
Morgan Stanley lowered its price target on United Therapeutics on July 19, 2025.Some support1 report
-
Revivicor is a subsidiary of United Therapeutics Corporation.Some support1 report
-
Leerink partners maintained a Buy rating on United Therapeutics stock on July 28, 2025.Some support1 report
-
United Therapeutics reported its financial metrics in the US.Some support1 report
-
United Therapeutics underperformed the S&P 500 so far this year.Some support4 reports
-
United Therapeutics' company performance was compared against the industry growth forecast.Some support2 reports
-
United Therapeutics announced an expanded partnership with MannKind, covering a new development product.Well supported4 reports
-
UBS predicts high sales potential for Tyvaso, a drug whose market success is linked to NIH data and the broader treatment landscape.Some support2 reports1 development inside
-
Deutsche Bank upgraded its stock rating to Buy on September 3, 2025, amidst market volatility driven by oil and metal prices.Some support1 report
-
Rival company United Therapeutics outperformed Zoetis stock on September 5, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
What's reaching United Therapeutics
Events traced to United Therapeutics, step by step, newest firstAround United Therapeutics this week
News at the entities that move United Therapeutics most-
SEC StructuralCelularity, Inc. filed with the SEC regarding its stock ownership on October 21, 2026.Moves United Therapeutics
-
Bank of America Mentioned togetherFinancial institutions including Barclays, Morgan Stanley, and Bank of America provided analyst coverage and target price reports for Sonic Automotive on May 27, 2026.Moves United Therapeutics
-
Securities and Exchange Commission StructuralETF filing with the SEC shows institutional activity for the Franklin Ethereum ETF.Moves United Therapeutics
-
Anheuser-Busch TransactionalKevin, who previously held senior finance roles at Anheuser-Busch, is joining ATIS, where Jim Fox serves as CEO.Moves United Therapeutics
-
MannKind Corporation OperationalMannKind Corporation and Monte Rosa Therapeutics were listed on the Nasdaq stock exchange on October 15, 2026.Moves United Therapeutics
-
FDA StructuralCongress and the Senate are considering legislation affecting FDA submissions and drug patent rights.Moves United Therapeutics
Connections
The 30 strongest of 75, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
SEC Structural
United Therapeutics is subject to formal disclosure and regulatory requirements mandated by the SEC.
-
Martine Rothblatt Structural
Martine Rothblatt serves as the CEO and Chairperson of United Therapeutics, directing company strategy and operations.
-
Securities and Exchange Commission Structural
United Therapeutics is subject to formal regulation and disclosure requirements mandated by the Securities and Exchange Commission.
-
Anheuser-Busch Transactional
United Therapeutics purchased a former brewery site belonging to Anheuser-Busch.
-
MannKind Corporation Operational
The companies are engaged in an ongoing partnership involving joint drug development, supply of clinical trial materials, and a shared royalty stream.
-
FDA Structural
The FDA is evaluating the NDA submission for LungFX, the product of United Therapeutics.
-
chairperson Structural
The individual holds the leadership role responsible for the company's operations during Q2 CY2026.
-
Insmed Operational
The companies actively compete in PAH treatments while Insmed supplies a critical prodrug component for United Therapeutics' drug.
Show all 30 connections
-
Nasdaq Structural
United Therapeutics is a publicly listed company on the Nasdaq stock exchange.
-
Biogen Operational
The two companies actively compete in the market as therapeutics stocks, with market performance and results influencing the other's standing.
-
UBS Mentioned together
UBS provides financial analysis, price targets, and rating coverage on United Therapeutics.
-
Bank of America Mentioned together
Bank of America provides financial analysis, including price targets and ratings, for United Therapeutics.
-
Baylor College of Medicine Structural
The companies maintain a research agreement focused on xenotransplantation to address organ shortages.
-
Royal Bank of Canada Mentioned together
Royal Bank of Canada provides financial analysis, target price updates, and rating recommendations for United Therapeutics shares.
-
Zenas Operational
The evidence suggests both entities are healthcare companies actively competing for market share.
-
Leerink partners Mentioned together
Leerink Partners provides investment ratings and coverage on United Therapeutics stock.
-
Norges Bank Transactional
Norges Bank purchased a new stake in shares of United Therapeutics.
-
MarketBeat Mentioned together
MarketBeat provides financial ratings and coverage for United Therapeutics.
-
Briefing.com Mentioned together
Briefing.com reports United Therapeutics' quarterly earnings data.
-
Minnesota Shared context
United Therapeutics is establishing and completing facilities construction within the geographical boundaries of Minnesota.
-
TD Cowen Mentioned together
TD Cowen issued a buy rating on United Therapeutics stock.
-
Moderna Mentioned together
Moderna and United Therapeutics are co-mentioned as companies operating within the therapeutics industry segment.
-
Merrimack Shared context
United Therapeutics operates within the geographic boundaries of the town of Merrimack.
-
Cantor Fitzgerald Mentioned together
Cantor Fitzgerald provides analyst coverage, raising price targets and reiterating ratings for United Therapeutics.
-
Jefferies Financial Group Mentioned together
Jefferies Financial Group provided a buy rating and price target for United Therapeutics.
-
Morgan Stanley Mentioned together
Morgan Stanley provides financial analysis and sets price targets for United Therapeutics.
-
Texas Shared context
United Therapeutics is completing facilities construction within the state of Texas.
-
Chris Prentiss Mentioned together
A is mentioned in the context of discussing the revenue streams of B, suggesting a professional or analytical connection.
-
Raymond James Financial Mentioned together
Raymond James Financial initiated coverage of United Therapeutics.
-
Dean Kamen Mentioned together
No evidence was provided linking United Therapeutics and Dean Kamen.
History
Events by the month they beganOctober 2026
3 eventsSeptember 2026
2 eventsAugust 2026
2 eventsShow 2 earlier months
July 2026
4 events- Various financial institutions, including Royal Bank of Canada, Bank of America, Raymond James Financial, TD Cowen, Cantor Fitzgerald, and MarketBeat, issued rating and price target updates regarding United Therapeutics on July 10, 2026.
- Norges Bank purchased a new stake in shares of United Therapeutics on July 24, 2026.
- United Therapeutics disclosed stock sales by CEO Martine Rothblatt via required SEC filing.
- The FDA granted premarket approval for the LungFX device for use with United Therapeutics, while Leerink partners maintained an Outperform rating on the company's shares.
June 2026
24 events- United Therapeutics filed Form 13F with the Securities and Exchange Commission.
- Trump's tariff plan caused markets to tank, affecting company Flo.
- HCRx provided $50M funding to Liquidia, accelerating YUTREPIA's commercial launch while United Therapeutics filed an injunction request.
- United Therapeutics filed required documents for executive stock transactions and listed its stock on the exchange.
- Filing required for institutional investment disclosures by Synaptics with the SEC.
- United Therapeutics filed disclosures with the Securities and Exchange Commission on June 16, 2026.
- Analyst report boosted United Therapeutics' price target from $525 to $625.
- UTHR stock benefits from Trump-era tariffs and onshoring.
- United Therapeutics is a biotech company based in Silver Spring, Maryland.
- Martine Rothblatt, CEO, provided company strategy updates for United Therapeutics on June 25, 2025.
- United Therapeutics provided updates on operational efficiency and trial standardization efforts in August 2025.
- UBS adjusted its price target on United Therapeutics on June 30, 2025.
- Moderna and United Therapeutics are companies operating in the therapeutics industry.
- United Therapeutics and Gilead Sciences are identified as major players in the therapeutics industry.
- Morgan Stanley lowered its price target on United Therapeutics on July 19, 2025.
- Revivicor is a subsidiary of United Therapeutics Corporation.
- Leerink partners maintained a Buy rating on United Therapeutics stock on July 28, 2025.
- United Therapeutics reported its financial metrics in the US.
- United Therapeutics underperformed the S&P 500 so far this year.
- United Therapeutics' company performance was compared against the industry growth forecast.
- United Therapeutics announced an expanded partnership with MannKind, covering a new development product.
- UBS predicts high sales potential for Tyvaso, a drug whose market success is linked to NIH data and the broader treatment landscape.
- Deutsche Bank upgraded its stock rating to Buy on September 3, 2025, amidst market volatility driven by oil and metal prices.
- Rival company United Therapeutics outperformed Zoetis stock on September 5, 2025.